The One Number On This Panel That Just Matches

The row, and the thirteen it sits beside

Gelagen’s supplement facts panel prints pantothenic acid at 5.2 mg per two-gummy serving. Nothing about that figure is unusual on its face; it sits in the middle of a fourteen-row panel, between vitamin B12 and the panel’s trace minerals, printed without a percentage of Daily Value beside it because pantothenic acid does not carry an established Daily Value under current labeling regulations. What makes the row worth a piece of its own is not the number alone but what it looks like next to the federal reference figure for the nutrient: an Adequate Intake of 5 mg for adults. 5.2 against 5 is a two-tenths-of-a-milligram gap, a four percent margin above the reference point. No other row on this panel sits that close to its own reference figure; the other thirteen are printed at fractions well below their RDA or Daily Value, or at multiples well above it, as earlier pieces on this journal on what a Daily Value actually measures and on the B12 row have each shown from opposite directions. Pantothenic acid is the one row that simply matches.

An Adequate Intake is not an RDA, and that matters here

Before doing anything with the arithmetic, it is worth being precise about what kind of reference figure 5 mg actually is. The NIH Office of Dietary Supplements’ health professional fact sheet on pantothenic acid states the adult reference intake as an Adequate Intake, not a Recommended Dietary Allowance. The distinction is not cosmetic. A Recommended Dietary Allowance is set when there is enough evidence to calculate the average requirement of a nutrient across a population and then add a margin that covers the needs of nearly all healthy individuals in a life-stage group. An Adequate Intake is used instead when the evidence is not sufficient to calculate that kind of population requirement with confidence, and it is instead set at a level assumed, based on observed healthy intakes, to be adequate. Pantothenic acid deficiency is genuinely rare in humans eating an ordinary diet, precisely because the nutrient is widely distributed across plant and animal foods; the name itself, from the Greek for “from everywhere,” reflects that distribution. That rarity of deficiency is part of why an AI, rather than a more tightly calculated RDA, is the figure that exists for pantothenic acid at all.

This matters for reading the 5.2 mg row correctly. A figure printed close to an RDA is a figure sitting close to a number calculated to cover nearly the whole healthy population with a built-in margin. A figure printed close to an Adequate Intake is sitting close to a looser, observationally-derived estimate of what ordinary healthy intake already looks like. Landing close to an AI is a smaller, more modest kind of claim than landing close to an RDA would be, and this article treats it as exactly that: a case study in what an unremarkable, adequately-dosed row looks like, not a case study in a row precisely tuned to a rigorously calculated population requirement.

5.2 against 5: the arithmetic, done plainly

5.2 mg is 104% of the 5 mg Adequate Intake. That is the entire calculation, and it is worth stating that plainly because the point of this piece is how unremarkable that number is, not how impressive it is. A single two-gummy serving of Gelagen supplies slightly more than the AI for pantothenic acid and nothing more dramatic than that. There is no multiple-of-the-reference-figure story to tell here the way there is with a row like B12 at 250% of its Daily Value, and there is no shortfall story to tell either, the way there is with a row like the panel’s 20 mg of vitamin C against a 75 to 90 mg RDA. The pantothenic acid row is neither generous nor thin against its own reference point; it simply, almost exactly, matches it.

Set against those three other rows, each covered in its own piece on this journal, the pantothenic acid figure is the outlier by being the least remarkable of the four, which is exactly the property that makes it worth writing about once, in a category of label writing that otherwise tends to focus on the rows that are unusually high or unusually low.

Why a formulator would land this close, on purpose or not

A figure that lands within four percent of a reference point can happen for a few different, entirely ordinary reasons, and this article is not in a position to state which one explains Gelagen’s own formulation, because that would require information no public source discloses: the manufacturer’s own formulation notes. One plausible route is a raw-material one. Pantothenic acid is typically supplied to manufacturers as calcium pantothenate, a stable salt form, and the amount of that raw material that translates to a clean, round unit dose can produce a finished-product figure that is close to, but not precisely equal to, a target reference number once rounding, overage for shelf-life stability, and blending with the product’s other twelve nutrients are accounted for. A second plausible route is a deliberate one: a formulator setting out to cover the Adequate Intake for this specific nutrient, with a small margin added for manufacturing variance, and 5.2 mg is a perfectly ordinary result of that kind of target. Both explanations are consistent with what is printed on the label; neither can be confirmed from the label alone, and this piece does not claim to know which applies.

What pantothenic acid actually does in the body

The ODS fact sheet describes pantothenic acid’s central role as a building block of coenzyme A, a molecule required in dozens of metabolic reactions throughout the body, including the metabolism of carbohydrates, proteins and fats for energy, and the synthesis of essential fatty acids, cholesterol, and several hormones. Coenzyme A is one of the more genuinely load-bearing molecules in human metabolism, which is part of why pantothenic acid deficiency, on the rare occasions it has been documented, tends to appear alongside deficiencies of other B vitamins rather than in isolation, typically in cases of severe, general malnutrition rather than from an ordinary diet missing one specific food group. The fact sheet’s own framing is consistent with that picture: because the nutrient is so widely distributed across ordinary foods, meaningfully undershooting the Adequate Intake through diet alone is uncommon in populations with reasonably varied access to food.

This is also a useful contrast with the panel’s other B-vitamin rows. B12’s own piece on this journal describes a nutrient whose real-world adequacy problem is concentrated in absorption, in specific populations, rather than in ordinary dietary intake. Pantothenic acid does not have that same absorption story attached to it in the ODS material; its adequacy story is overwhelmingly about how common the nutrient already is across an ordinary diet, which is precisely why an intake close to the reference figure, rather than dramatically above or below it, is the unremarkable, expected shape for this particular row to take.

No upper limit, for a different reason than B12

Gelagen’s own panel states that no upper limit has been set for pantothenic acid, the same statement it makes about B12. The underlying reason is not identical between the two nutrients, though both point toward the same low-toxicity conclusion. For B12, this journal’s earlier piece describes a saturable, receptor-limited absorption pathway that caps how much of a large dose actually gets taken up. For pantothenic acid, the ODS fact sheet instead points to a simple lack of documented adverse effects at intake levels studied to date as the basis for the Food and Nutrition Board not establishing a Tolerable Upper Intake Level, rather than describing a specific absorption bottleneck of the kind that limits B12 uptake. The practical conclusion is similar — no established ceiling, low reported toxicity — but the evidentiary path NIH describes to reach that conclusion is different for each nutrient, and conflating the two would overstate how much is actually known about pantothenic acid’s upper safety margin specifically.

Why deficiency evidence for this nutrient looks the way it does

Part of why pantothenic acid ended up with an Adequate Intake rather than a more tightly calculated RDA is historical as well as biochemical. The ODS fact sheet traces documented human deficiency largely to two circumstances: controlled experiments in which researchers used a pantothenic acid antagonist to deliberately induce a deficiency state in volunteers, and observations in prisoners of war during the Second World War who were severely malnourished and reported a specific burning, tingling sensation in the feet, a symptom that resolved with pantothenic acid repletion and became known descriptively as “burning feet syndrome.” Outside of severe general malnutrition or deliberate experimental depletion, spontaneous, isolated pantothenic acid deficiency from an ordinary diet is not well documented in the literature the fact sheet summarizes. That thin evidence base for naturally occurring deficiency is precisely the kind of gap that leads the Food and Nutrition Board to set an Adequate Intake, built from observed healthy intake levels, rather than an RDA built from a calculated population requirement with a statistical margin added on top.

This history matters for reading the 5.2 mg row honestly. It is not that pantothenic acid is unimportant; coenzyme A's role described above makes clear that it is metabolically indispensable. It is that the specific reference number printed on this label, 5 mg, is a softer, more observational kind of figure than the RDA sitting beside the B12 or vitamin C rows on the same panel, and a printed amount landing close to that softer figure is making a correspondingly modest claim: ordinary adequacy, not a documented correction of a common, measurable shortfall.

What "adequate" pricing looks like on a label

Put the pieces of this article together and the pantothenic acid row reads less like a headline ingredient and more like a quiet confirmation that this particular box on the formulation checklist has been filled adequately rather than generously or thinly. That is not a criticism of the row, and it is not praise for it either; it is simply what the arithmetic shows when it is done plainly rather than rounded toward a more dramatic story in either direction. A reader scanning a Supplement Facts panel for rows that stand out, the way the vitamin D row or the B12 row each do for different reasons, will likely pass over the pantothenic acid line without a second look, and on the evidence gathered here, that is a reasonable thing to do: a number that lands almost exactly on its own reference figure is, definitionally, the least remarkable amount that row could print.

Sources for this article